Bolt Biotherapeutics, Inc. (BOLT) · Oct 23, 2026 · Acquisition
Prana acquisition — 13,995.311 Series D shares plus warrants; related financing totals $120 million
Bolt Biotherapeutics’ acquisition and financing broaden the pipeline and extend funding, but new investors and Prana holders will dominate the post-deal ownership.
Bolt is a cash-constrained clinical-stage oncology biotech centered on the BDC-4182 Phase 1/2 program, with $18.1 million in cash and marketable securities at June 30, 2026 and management warning that its resources raised substantial doubt about continuing as a going concern. This filing supplies a much larger strategic reset than a routine registration notice. It documents the legal machinery for acquiring Prana Therapies while issuing up to 13,995.311 shares of Series D non-voting convertible preferred stock and accompanying warrants. 〔0〕 〔1〕
The transaction addresses Bolt’s funding problem, but the financing is not a free extension of the old story. The related announcement describes a $120 million private placement, with up to another $60 million available through warrants, giving Bolt materially more runway than its pre-filing balance sheet. The preferred stock is convertible into common equity subject to stockholder approval and ownership limits, while the registration agreement gives investors a path to resell the converted shares. 〔2〕
The buried cost is a change in who owns and controls the company. The financing and merger announcement indicates that legacy Bolt holders would retain only about 6.9% of the post-transaction common equity on a fully diluted basis, versus roughly 51.7% for former Prana holders and 41.4% for the new financing investors. That makes this closer to a recapitalization and corporate reset than a simple bolt-on acquisition: Bolt gets capital and a new asset base, but existing holders give up most of the economic ownership.
The registration rights themselves are investor protection, not new operating progress. Bolt must file an initial resale registration statement within 75 days of closing and generally faces liquidated damages of 1.0% of an investor’s purchase price per 30-day delay, capped at 5.0%. 〔3〕 This increases the investors’ ability to exit, while leaving the business case dependent on the Prana combination and Bolt’s upcoming BDC-4182 clinical readout.
Bottom line: The deal meaningfully improves Bolt’s financing position and broadens the platform, but it does so by transferring most post-deal ownership to Prana holders and new investors. This is a company reset with real strategic upside and very heavy dilution, not merely a capital raise.
Shareholder approval, merger closing, and BDC-4182 data
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!